Shares of Entrada Therapeutics (NASDAQ: TRDA) tanked more than 30% in pre-market trading on Tuesday after the U.S. FDA placed a clinical hold on TRDA’s Investigational New Drug Application (IND) for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The biopharma company “plans to share additional updates pending further communications with the Agency.”
TRDA stock has risen by more than 40% in the past year.
